Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Scholar Rock Holding (SRRK – Research Report). The associated price target was raised to $40.00. Andres Y. Maldonado ...

TD Cowen analyst Marc Frahm has maintained their bullish stance on SRRK stock, giving a Buy rating today. Marc Frahm has given his Buy rating due to a combination of factors including promising trial ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients Scholar Rock (SRRK), a Phase 3, clinical-stage ...